Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutivacaftor (Primary) ; Tezacaftor (Primary) ; Vanzacaftor (Primary) ; Ivacaftor; Ivacaftor/tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals

Most Recent Events

  • 28 Jul 2021 According to Vertex Pharmaceuticals Media Release, complete data from this trial will be presented at a later date
  • 28 Jul 2021 Primary endpoint (Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)) has been met as per Vertex Pharmaceuticals Media Release
  • 28 Jul 2021 Results published in the Vertex Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top